Articles
Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders
People with haematological disorders are frequently at risk of severe or life‐threatening bleeding as a result of thrombocytopenia (reduced platelet count).
Platelet transfusions are not without risk and adverse events may be life‐threatening. A possible adjunct to prophylactic platelet transfusions is the use of antifibrinolytics, specifically the lysine analogues tranexamic acid (TXA) and epsilon aminocaproic acid (EACA).
Click here to access the article.